PDF
ePub
Citation
Print
Abstract
Purpose
In the present study, the effect of the inferior conjunctival transposition flap in patients with recurrent pterygium was evaluated.
Methods
This study included 60 patients (63 eyes) that received pterygium surgery with inferior conjunctival transposition flap and diagnosed with recurrent pterygium. The inferior conjunctival transposition flap obtained from lower bulbar conjunctiva was secured with 8–0 VICRYL® after removal of recurrent fibrovascular tissues. This study was retrospectively reviewed for recurrence and postoperative complications in patients with a minimum follow-up period over 6 months.
Results
The mean follow-up period was 5 years and 8 months (range; 6 months to 14 years). Corneal recurrence occurred in 4 eyes (6.3%) and conjunctival recurrence was observed in 2 eyes (3.1%) among a total of 63 eyes. Conjunctival recurrence was not the progressive type and limited to the limbus and suture site. One case of corneal recurrence required additional symblepharolysis and auto conjunctival graft. Although mild flap congestion, hemorrhage and granuloma were observed, these cases improved during the follow-up period.
References
1. Rosenthal JW. Chronology of pterygium therapy. Am J Ophthalmol. 1953; 36:1601–16.
2. Coroneo MT. Pterygium as an early indicator of ultraviolet in-solation: a hypothesis. Br J Ophthalmol. 1993; 77:734–9.
3. Saw SM, Tan D. Pterygium: prevalence, demography and risk factors. Ophthalmic Epidemiol. 1999; 6:219–28.
4. Morgan DJ, Hollows FC. Pterygium and ultraviolet radiation: a positive correlation. Br J Opthalmol. 1984; 68:343–6.
5. Coroneo MT, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol. 1999; 10:282–8.
6. Mckeown CM, Harris R. An autosomal dominant multiple abdominal syndrome. J Med Genet. 1988; 25:96–103.
7. Mackenzie FD, Hirst LW, Battistutta D, Green A. Risk analysis in the development of pterygia. Ophthalmology. 1992; 99:1056–61.
8. Tananuvat N, Martin T. The results of amniotic membrane abdominal for primary pterygium compared with conjunctival autograft. Cornea. 2004; 23:458–63.
9. Ehrlich D. The management of pterygium. Ophthalmic Surg. 1977; 8:23–30.
10. Hirst LW, Sebban A, Chant D. Pterygium recurrence time. Ophthalmology. 1994; 101:755–8.
11. Shehadeh-Mashor R, Srinivasan S, Boimer C, et al. Management of recurrent pterygium with intraoperative mitomycin C and abdominal autograft with fibrin glue. Am J Ophthalmol. 2011; 152:730–2.
12. Taylan Sekeroglu H, Erdem E, Dogan NC, et al. Sutureless abdominal membrane transplantation combined with narrow-strip abdominal autograft for pterygium. Int Ophthalmol. 2011; 31:433–8.
13. Mutlu FM, Sobaci G, Tatar T, Yildirim E. A comparative study of recurrent pterygium surgery: limbal conjuctival autograft abdominal versus mitomycin C with conjunctival flap. Ophthalmology. 1999; 106:817–21.
14. Kim S, Yang Y, Kim J. Primary pterygium surgery using the abdominal conjunctival transposition flap. Ophthalmic Surg Lasers. 1998; 29:608–11.
15. Prabhasawat P, Barton K, Burkett G, Tseng SC. Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology. 1997; 104:974–85.
16. Bahrassa F, Datta R. Postoperative beta radiation treatment of pterygium. Int J Radiat Oncol Biol Phys. 1983; 9:679–84.
17. Mauro J, Foster CS. Pterygia: pathogenesis and the role of subabdominal bevacizumab in treatment. Semin Ophthalmol. 2009; 24:130–4.
18. Chen CW, Huang HT, Bair JS, Lee CC. Trabeculectomy with abdominal topical application of mitomycin-C in refractory glaucoma. J Ocul Phamacol. 1990; 6:175–82.
19. Frucht-Pery J, Ilsar M. The use of low-dose mitomycin C for abdominalion of recurrent pterygium. Ophthalmology. 1994; 101:759–62.
20. Carrasco MA, Rapuano CJ, Cohen EJ, Laibson PR. Scleral abdominal after preoperative injection of mitomycin C in the pterygium head. Arch Ophthalmol. 2002; 120:1585–6.
21. Peponis V, Rosenberg P, Chalkiadakis SE, et al. Fungal scleral abdominal and endophthalmitis following pterygium excision. Eur J ophthalmol. 2009; 19:478–80.
22. Rubinfeld RS, Pfister RR, Stein RM, et al. Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology. 1992; 99:1647–54.
23. Lindquist TP, Lee WB. Mitomycin C-associated scleral stromal-ysis after pterygium surgery. Cornea. 2015; 34:398–401.
24. Lam DS, Wong AK, Fan DS, et al. Intraoperative Mitomycin C to Prevent Recurrence of Pterygium after Excision: A 30 Months Follow-up Study. Ophthalmology. 1998; 105:901–4. discussion 904–5.
25. Tarr KH, Constable IJ. Late complications of pterygium treatment. Br J Ophthalmol. 1980; 64:496–505.
26. Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in pterygium. Acta Histochem. 1996; 98:195–201.
27. Aspiotis M, Tsanou E, Gorezis S, et al. Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye (Lond). 2007; 21:1095–101.
28. Fallah MR, Khosravi K, Hashemian MN, et al. Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res. 2010; 35:17–22.
29. Lekhanont K, Patarakittam T, Thongphiew P, et al. Randomized controlled trial of subconjunctival bevacizumab injection in abdominal recurrent pterygium: a pilot study. Cornea. 2012; 31:155–61.
30. Erdumus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007; 245:1577–9.
31. Mansour AM. Treatment of inflamed pterygia or residual pterygial bed. Br J Ophthalmol. 2009; 93:864–5.
32. Razeghinejad MR, Hosseini H, Ahmadi F, et al. Preliminary results of subconjunctival bevacizumab in primary pterygium excision. Ophthalmic Res. 2010; 43:134–8.
33. Kenyon KR, Wagoner MD, Hettinger ME. Conjunctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology. 1985; 92:1461–70.
34. Hirst LW. Recurrent pterygium surgery using pterygium extended removal followed by extended conjunctival transplant: recurrence rate and cosmesis. Ophthalmology. 2009; 116:1278–86.
35. Mery G, Maalouf T, George JL, Angioi K. Limbal-conjunctival abdominal in pterygium surgery. J Fr Ophthalmol. 2010; 33:92–8.
36. McCoombes JA, Hirst LW, Isbell GP. Sliding conjunctival flap for the treatment of primary pterygium. Ophthalmology. 1994; 101:169–73.
37. Lei G. Surgery for pterygium using a conjunctival pedunculated flap slide. Br J Ophthalmol. 1996; 80:33–4.
38. Cho JW, Chung SH, Seo KY, Kim EK. Conjunctival mini-flap technique and conjunctival autotransplantation in pterygium surgery. J Korean Ophthalmol Soc. 2005; 46:1471–7.
39. Hong SM, Ko SJ, Kim SD. Effect of inferior conjunctival abdominal flap surgery for primary pterygium. J Korean Ophthalmol Soc. 2009; 50:1774–9.
40. Adamis AP, Starck T, Kenyon KR. The management of pterygium. Ophthalmol Clin North Am. 1990; 3:611–23.
41. Pan HW, Zhong JX, Jing CX. Comparison of fibrin glue versus abdominal for conjunctival autografting in pterygium surgery: a metaanalysis. Ophthalmology. 2011; 118:1049–54.
42. Mandour SS, Farahat HG, Mohamed HM. Preoperative sub-pterygial mitomycin C injection versus limbal conjunctival abdominal transplantation for prevention of pterygium recurrence. J Ocul Phamacol Ther. 2011; 27:481–5.
43. Barbosa JB, De Farias CC, Hirai FE, Pereira Gomes J. Amniotic membrane transplantation with narrow-strip conjunctival autograft vs conjunctival autograft for recurrent pterygia. Eur J Ophthalmol. 2016; Jul 12:0. doi:. DOI: 10.5301/ejo.5000773. [Epub ahead of print].
44. Al Fayez MF. Limbal versus conjunctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology. 2002; 109:1752–5.
Figure 1
Surgical technique of the inferior conjunctival transposition flap. (A) The pterygial tissue was removed as indicated by the incisional marking (dotted line). (B) The conjunctival flap was made from the inferior conjunctiva near limbus. (C) The conjunctival flap was transpositioned with rotation to the excision site of pterygium. (D) The conjunctival flap was secured to adjacent conjunctiva with few interrupted sutures of 8–0 vicryl.
Figure 2
Anterior segment photographies of the corneal recurrence patient. (A) Before surgery. (B) Grade 3 recurrence of pterygium after surgery. The fibrovascular tissue was observed to invade cornea at the postoperative 4 months. In the comparison of pre-operative and postoperative photograph, it showed that the aspect of recurred pterygium after surgery was mild in size and fibrosis.
Figure 3
Anterior segment photographies of the conjunctival recurrence patient. (A) Before surgery. (B) Grade 2 recurrence of pterygium after surgery. The limbal fibrovascular tissue was observed at the postoperative 6 months. This aspect of fibrovascular tissue becames inflamed slightly weaker, less vascularized, non-progressive than before surgery.
Figure 4.
Complications after inferior conjunctival transposition flap surgery. (A) Pterygium recurrence associated with sym-blepharon attached to lower lid was observed in five months. For treatment, additional surgery of symblepharolysis and au-to-conjunctival graft was required. (B) The granuloma was observed in tenon capsule three weeks after surgery. It improved during the observation to respond well to steroid therapy. (C) The ocurrence of conjunctival cyst was seen in the 3 months of postoperative observation.
Table 1.
Patient characteristics
XML Download